Nothing Special   »   [go: up one dir, main page]

MX2023012703A - Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave. - Google Patents

Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave.

Info

Publication number
MX2023012703A
MX2023012703A MX2023012703A MX2023012703A MX2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A MX 2023012703 A MX2023012703 A MX 2023012703A
Authority
MX
Mexico
Prior art keywords
antibody
myasthenia gravis
treat
treat myasthenia
inebilizumab
Prior art date
Application number
MX2023012703A
Other languages
English (en)
Inventor
Eliezer Katz
John N Ratchford
Liron Abuhsira
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2023012703A publication Critical patent/MX2023012703A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se describen métodos para usar un anticuerpo anti-CD19 para tratar enfermedades autoinmunitarias. En particular, la descripción proporciona el uso de Inebilizumab, un anticuerpo monoclonal IgG1 kappa humanizado, optimizado por afinidad y afucosilado para tratar la miastenia grave.
MX2023012703A 2021-05-07 2022-05-06 Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave. MX2023012703A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185613P 2021-05-07 2021-05-07
US202263303655P 2022-01-27 2022-01-27
PCT/US2022/028063 WO2022236047A1 (en) 2021-05-07 2022-05-06 Use of an anti-cd19 antibody to treat myasthenia gravis

Publications (1)

Publication Number Publication Date
MX2023012703A true MX2023012703A (es) 2023-11-21

Family

ID=81846343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012703A MX2023012703A (es) 2021-05-07 2022-05-06 Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave.

Country Status (10)

Country Link
US (1) US20240270842A1 (es)
EP (1) EP4333987A1 (es)
JP (1) JP2024518410A (es)
KR (1) KR20240004367A (es)
AU (1) AU2022270697A1 (es)
BR (1) BR112023022133A2 (es)
CA (1) CA3217586A1 (es)
IL (1) IL308296A (es)
MX (1) MX2023012703A (es)
WO (1) WO2022236047A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
KR101287395B1 (ko) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
RS20120253A1 (en) 2001-05-24 2013-02-28 Zymogenetics Inc. TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
JP2007536896A (ja) 2003-06-05 2007-12-20 ジェネンテック・インコーポレーテッド Ｂｌｙｓアンタゴニストとその用途
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2008311815B2 (en) * 2007-10-19 2014-02-06 Seagen Inc. CD19 binding agents and uses thereof
US8679492B2 (en) * 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
CN106794231A (zh) 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
CN108699155B (zh) 2016-03-01 2023-03-21 豪夫迈·罗氏有限公司 具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
BR112021020924A2 (pt) * 2019-04-24 2022-04-19 Viela Bio Inc Uso de um anticorpo anti-cd19 para tratar doença autoimune

Also Published As

Publication number Publication date
WO2022236047A1 (en) 2022-11-10
EP4333987A1 (en) 2024-03-13
IL308296A (en) 2024-01-01
US20240270842A1 (en) 2024-08-15
AU2022270697A1 (en) 2023-10-19
WO2022236047A9 (en) 2023-09-21
CA3217586A1 (en) 2022-11-10
BR112023022133A2 (pt) 2023-12-26
KR20240004367A (ko) 2024-01-11
JP2024518410A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2021012870A (es) Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
CR20200100A (es) Conjugado de anticuerpo monoclonal contra bcma -fármaco
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
ZA202400108B (en) A group of b7h3 monoclonal antibodies and medical use thereof
MX2020011997A (es) Anticuerpo anti glicoproteina de transmembrana mucina-1 (muc1).
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
ZA202008095B (en) Humanized antibodies against psma
MA39821A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
WO2020113224A3 (en) Chimeric antigen receptor factories and methods of use thereof
NZ595863A (en) Antibodies to egfl7 and methods for their use
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
MX2020013428A (es) Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
EP1357132A3 (en) Detection of the her2 receptor by means of biotinylated humanized antibody
MX2023012703A (es) Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave.
MX2022008687A (es) Receptores de antígenos quiméricos para la eliminación de amiloide.
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
EP3752535A4 (en) MONOCLONAL ANTIBODY PRODUCTION PROCESS HU14.18K322A
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
EP3889180A4 (en) ANTI-OX40 HUMANIZED MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
MX2023004794A (es) Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias.
MX2021012488A (es) Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
MX2023005699A (es) Anticuerpos biespecificos para el uso en el tratamiento de inflamasomopatia nlrc4-gof.